Standout Papers

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with pr... 2018 2026 2020 2023 480
  1. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study (2018)
    Courtney D. DiNardo, Keith W. Pratz et al. The Lancet Oncology

Immediate Impact

4 by Nobel laureates 38 from Science/Nature 65 standout
Sub-graph 1 of 22

Citing Papers

Exploiting senescence for the treatment of cancer
2022 Standout
Copper induces cell death by targeting lipoylated TCA cycle proteins
2022 StandoutScience
5 intermediate papers

Works of Mack Mabry being referenced

A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors
2014
RREB-1, a Novel Zinc Finger Protein, Is Involved in the Differentiation Response to Ras in Human Medullary Thyroid Carcinomas
1996
and 2 more

Author Peers

Author Last Decade Papers Cites
Mack Mabry 1198 525 597 31 1.8k
Karin D. Berg 917 722 631 29 2.2k
H P Koeffler 832 506 424 34 1.8k
Tsz Kan Fung 1436 496 417 27 1.9k
Björn Hackanson 1229 336 573 50 1.7k
Josiane Grosgeorge 1982 656 488 32 3.1k
Nathalie A. Lokker 1047 462 472 28 2.1k
M. S. Berger 857 939 469 37 2.1k
Kurt Grünewald 892 667 338 29 2.1k
Jing Yang 1138 581 531 54 1.9k
Stephan M. Tanner 1404 356 526 44 2.3k

All Works

Loading papers...

Rankless by CCL
2026